Development of psychedelic medicine to treat mental health-related medical conditions such as depression, anxiety, addiction, and trauma-related stress disorder.
We are developing industrial-scale production methodology of pharmaceutical-grade psychedelic compounds, including psilocybin and mescaline. Our hope is to support further research into their potential as treatment options for mental health-related medical conditions.
We are focused on applying Bionxt’s drug formulation expertise and Vektor’s proven drug delivery platforms to emerging psychedelic APIs. This has the potential to create standardized drug formulations with safe and precise dosing for clinical study and therapeutic use.
We are planning clinical programs to test and validate our psychedelic drug formulations in the treatment of addiction and depression. Stay tuned for further developments.
New opportunities for psychedelic compounds
Our research and development in psychedelic treatments with modern scientific methods and validation has the potential to change the narrative on mental health-related medical conditions.
Be in the know. Get our press releases and latest news first.
Hear about our latest research, products, exclusive partnerships & more.